胚系遗传变异与癫痫手术反应:272例个体参与者汇总分析
本研究通过系统综述和个体参与者数据汇总,纳入272例携带致病/可能致病胚系变异(除外结节性硬化)并接受切除或激光消融的癫痫患者。末次随访时,血管病和GATORopathies的无发作率较高,而通道病和突触病较低,即使存在MRI病灶。结果提示手术疗效因遗传通路而异,需前瞻性基因型知晓的手术登记来优化候选者选择。
要点
- 胚系遗传癫痫手术无发作率因通路而异,血管病和GATORopathies最高。
- 通道病和突触病即使有MRI病灶,无发作率仍显著较低。
- 需前瞻性基因型知晓登记以优化手术候选者选择。
核心结论
- 切除性手术对胚系遗传癫痫有效,但无发作率因遗传通路而异。
- 具有离散病灶基质的疾病(GATORopathies、血管病)无发作可能性最高。
- 通道病和突触病即使存在MRI病灶,手术收益仍显著较低。
研究设计与样本
- 系统综述MEDLINE和Scopus,并加入3个机构队列和PERC数据库病例。
- 纳入致病/可能致病胚系变异(除外结节性硬化)并接受切除或激光消融的个体,共272例。
- 按生物学知情分类分组:GATORopathies、血管病、过度生长、拷贝数变异(CNVs)、通道病、突触病和其他。
主要发现
- 末次随访无发作率:血管病14/19(73.6%),GATORopathies 79/120(65.8%),CNVs 18/31(58.0%),过度生长9/16(56.6%),通道病13/43(30.0%),突触病4/18(22.2%),其他11/25(44.0%)(总体p < 0.001)。
- 有影像结果者中208/253(82.2%)存在致癫痫MRI病灶,包括64%的通道病和80%的突触病。
- 单变量对比中,血管病无发作OR 2.64(95% CI 0.87-9.65),GATORopathies OR 2.41(95% CI 1.44-4.09),突触病OR 0.23(95% CI 0.05-0.77),通道病OR 0.22(95% CI 0.09-0.48)。
- 预设敏感性分析(仅病灶性、仅文献、排除GATORopathies)中方向和幅度一致。
关键数值与推荐
- 无发作定义为Engel I。
- 中位随访24个月(四分位距12-48.0)。
- 组间比较使用Fisher精确检验和Kruskal-Wallis检验(α = 0.05;适用时Bonferroni校正)。
临床怎么用
- 术前遗传学结果可辅助预测手术无发作概率,血管病和GATORopathies患者获益可能性较高。
- 通道病和突触病患者即使有MRI病灶,也应谨慎评估手术预期。
- 需结合遗传通路进行个体化手术决策。
局限性
- 为个体参与者汇总分析,部分数据来自文献和登记库,可能存在选择偏倚。
- 中位随访24个月,长期结局不确定。
- 需前瞻性基因型知晓的手术登记和标准化报告(EEG、影像、病理)及时间-事件结局来验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Genetic testing is increasingly used in presurgical evaluation, but the yield of resection and ablation across germline genetic epilepsies remains uncertain. METHODS: We conducted a systematic review of MEDLINE (PubMed) and Scopus and added cases from 3 institutional cohorts and the Pediatric Epilepsy Research Consortium (PERC) databases, including individuals with pathogenic/likely pathogenic germline variants besides tuberous sclerosis who underwent resection or laser ablation. Etiologies were grouped into biologically informed categories (GATORopathies, vascular, overgrowth, copy number variants (CNVs), channelopathies, synaptopathies, and other). Primary outcome was seizure freedom (Engel I) at the last follow-up. Group comparisons used Fisher exact and Kruskal-Wallis tests (α = 0.05; Bonferroni when applicable). Prespecified sensitivity analyses stratified by lesional status, excluded GATORopathies, and restricted to literature-only cases. RESULTS: We included 224 literature cases (65 studies), 36 institutional cases, and 12 PERC cases (n = 272). The median follow-up was 24 months (interquartile range 12-48.0). Seizure freedom was achieved in vascular disorders 14/19 (73.6%), GATORopathies 79/120 (65.8%), CNVs 18/31 (58.0%), overgrowth 9/16 (56.6%), channelopathies 13/43 (30.0%), synaptopathies 4/18 (22.2%), and other 11/25 (44.0%) (overall p < 0.001). Among cases with available imaging results, 208/253 (82.2%) had epileptogenic MRI lesions, including 64% of channelopathies and 80% of the synaptopathies. In univariate contrasts (each category vs all others), odds of seizure freedom were higher for vascular disorders (2.64-fold, 95% CI 0.87-9.65) and GATORopathies (2.41-fold, 95% CI 1.44-4.09), and lower for synaptopathies (∼4.2-fold lower, OR 0.23, 95% CI 0.05-0.77) and channelopathies (∼4.5-fold lower, OR 0.22, 95% CI 0.09-0.48). Direction and magnitude were consistent across prespecified sensitivity analyses (lesional only, literature only, exclusion of GATORopathies). DISCUSSION: Resective surgeries can be effective in germline genetic epilepsies, but outcomes vary by pathway. Disorders with discrete, lesional substrates (GATORopathies, vascular) show the highest likelihood of seizure freedom, whereas channelopathies and synaptopathies, despite the presence of MRI lesions, have substantially lower yields even in lesional cases. Prospective, genotype-aware surgical registries with standardized reporting (EEG, imaging, and pathology) and time-to-event outcomes are needed to refine the selection of surgical candidates and quantify seizure and non-seizure-related outcomes.
引用
- Ivaniuk A, Bajaj S, Boßelmann CM, et al. Germline Genetic Variants and Epilepsy Surgery Response: Individual Participant Pooled Analysis of 272 Patients. Neurology. 2026. PMID: 42970749. doi:10.1212/WNL.0000000000218687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。